








Theoretical Interaction of a Series of Dibenzo Derivatives on Aldosterone Synthase Surface

Figueroa-Valverde Lauro ^{1,*}, López-Ramos Maria ^{1,*}, Rosas-Nexticapa Marcela ², Alvarez-Ramirez Magdalena ², Díaz-Cedillo Francisco ³, Mateu-Armad Maria Virginia ², López-Gutierrez Tomás ¹

¹ Laboratory of Pharmaco-Chemistry, Faculty of Chemical Biological Sciences, University Autonomous of Campeche, Av. Agustín Melgar s/n, Col Buenavista C.P. 24039 Campeche, Camp., México

² Faculty of Nutrición, University Veracruzana, Médicos y Odontólogos s/n C.P. 91010, Unidad del Bosque Xalapa Veracruz, México

³ National School of Biological Science, National Polytechnic Institute, Prol. Carpio y Plan de Ayala s/n Col. Santo Tomas, México, D.F. C.P. 11340

* Correspondence: lfiguero@uacam.mx (F.L.); maclopez@uacam.mx (L.M.);

Scopus Author ID 55995915500

Received: 7.11.2022; Accepted: 7.01.2023; Published: 24.02.2023

Abstract: Some reports indicate that Dibenzo derivatives can produce a broad spectrum of biological activities such as antibacterial, antiulcer, antiviral, and anticancer drugs. However, the molecular mechanism produced in the is not very clear; perhaps this phenomenon could be to differences involved in the chemical structure of Dibenzo derivatives (compounds 1-10). This investigation aimed to conduct The results displayed that Dibenzo analogs 1, 3-9 could act as aldosterone synthase inhibitors which translated as good compounds to decrease blood pressure.

Keywords: Dibenzo; aldosterone synthase; docking.

© 2023 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction


For several years, the development of benzo derivatives has increased both pharmacy and organic chemistry fields [1, 2]. For example, the synthesis of compounds dibenzo-pentaphene derivatives from a 1,5-dimethoxy-anthraquinone and ruthenium [3]. Other data shows the reaction of 2-halobenzaldehyde with 2-hydroxyphenyl)acetonitrile to form a dibenzo[b,f]oxepine [4]. Besides, a study showed the di-lithiation of 1-bromo-2-[(Z)-2-(2-bromophenyl)vinyl]benzene to give the methylated benzo[h]quinolyldibenzo-[b,f]silepin [5]. Another report displays the synthesis of a series o phenylamino-substituted 6,11-Dihydro-dibenzo[b,e]oxepin-11-ones which can produce biological activity against p38 mitogen-activated protein kinase [6] (which responsive to stress stimuli [7], heat shock [8], cell differentiation [9], apoptosis [10] and autophagia [11]). In addition, a dibenzo-chromone derivative (2-(4-ethylpiperazin-1-yl)-N-(4-(2-morpholino-4-oxo-4H-chromen-8-yl)dibenzo-[b,d]thiophen-1-yl)acetamide) was prepared from 8-Dibenzothiophen-4-yl-2-morpholin-4-yl-chroman-4-one as DNA-inducing cytotoxic agent [12]. Other data shows the synthesis of 10-methoxy-dibenzo[b,h][1,6]naphthyridinecarboxamide from ethyl-4-[(2-chloro-7-methoxyquinolin-3-yl)methyl]amino}benzoate and tri-tertbutylphosphine tetrafluoroborate with anticancerigenic activity [13]. Besides, some dibenzo derivatives (5-aryloxy-pyrazolyl)- and (5-aryl/olefin-sulfanyl-pyrazolyl)-dibenzo[b,e][1,4]-diazepinone) were prepared via binding 5-substituted 3-methyl-1-phenyl-pyrazole-4-carbaldehydes to cyclic diketones and aromatic

diamines; it is noteworthy that these compounds exert anticancerigenic activity in vitro [14]. Besides, a report displayed the preparation of a series of N-substituted 1H-dibenzo[a,c]carbazole derivatives as antimicrobial agents [15]. Other data showed the synthesis of some dibenzo derivatives such as 4,5-dihydrospiro[benzo[c]azepine-1,1'-cyclohexan]-3(2H)-ones via reaction of 7-bromospiro[4,5-dihydro-2H-2-benzazepine-1,1'-cyclohexane]-3-one with phenylboronic acid as PARP-1 (Poly [ADP-ribose] polymerase 1) inhibitors [16-19]. Recently, a theoretical study showed the possible affinity of a series of dibenzo[b,e][1,4]diazepines derivatives with dopamine D1 and D2 receptors [20]. All of these data indicate that various dibenzo derivatives may produce different effects in several biological systems; however, there are no studies on the interaction of some dibenzo analogs with the aldosterone synthase enzyme involved in blood pressure regulation [21, 22]. Therefore, a theoretical study was carried out in this investigation to evaluate the possible coupling of ten dibenzo derivatives with aldosterone synthase enzyme surface using DockingServer software [23].

2. Materials and Methods

2.1. General methodology.

A series of Dibenzo derivatives previously reported [24-33] were used to evaluate their theoretical interaction with aldosterone synthase enzyme surface (Figures 1-2) as follows:



- 1 = Dibenzo[b,f]oxepine [24]
- 2 = 10H-Dibenzo[b,e]Thiopyran [25]
- 3 = Dibenzo[b,d]furan-2-carboxylic acid [26]
- 4= Dibenzo[b,e]thiophen-11(6H)-one [27]
- 5 = 10H-Dibenzo[a,h]anthracen-7-ylamine [28]
- 6 = 1H-Dibenzo[b,d]furan-2-ol [29]
- 7 = 1H-Dibenzo[b,d]furan-3-amine [30]
- 8 = 1H-Dibenzo[b,d]thiophen-2-ol [31]
- 9 = 1H-Dibenzo[a,h]fluoren-13-one oxime [32]
- 10 = 1H-Dibenzo[a,h]anthracen-7-yl-Butanamide [33]

Figure 1. Structure chemical of Dibenzo derivatives (1-10).

2.2. Physicochemical parameters analysis.

The following electronic parameters such as HOMO (Highest Occupied Molecular Orbital), LUMO (Lowest Unoccupied Molecular Orbital) energy, orbital coefficients distribution, molecular dipole moment and HBD (hydrogen bond donor groups) and HBA (hydrogen bond acceptor groups) and PSA (polar surface area) were determined using the Spartan'06 software [34].

2.3. Pharmacophore model.

The 3D pharmacophore model for Dibenzo derivatives was evaluated using LigandScout software [35, 36].

2.4. Ligand-protein interaction.

The interaction of Dibenzo derivatives with aldosterone synthase enzyme surface was evaluated using 4fdh protein PDB DOI: 10.2210/pdb4FDH/pdb in complex with fradazole (4-(5,6,7,8-Tetrahydro-imidazo[1,5-a]pyridin-5-yl)-benzocnitrile) [37, 38] as theoretical tools. In addition, to evaluate the types of binding energy involved in the interaction of Dibenzo derivatives with 4fdh protein surface the DockingServer software was used [23].

3. Results and Discussion

3.1. Electronic energies.

Several electronic parameters have been used to predict the reactivity of various compounds; it is noteworthy that data suggests that the orbitals HOMO and LUMO values could condition the chemical reactivity of some compounds [39].




Figure 2. The LUMO-HOMO energy difference (ΔE) was used to predict the reaction activity of different dibenzo derivatives.

In this way, the HOMO and LUMO involved in the chemical structure of either compounds 1 to 10 were evaluated using Spartan '06 software [34]. The results show that the HOMO-LUMO gap value for compound 5 was in a similar form to 10; however, these values were different compared with values for compounds 1, 2-4, and 6-9 (Figure 2); this process could be conditioned by π orbitals, which is localized in dibenzo[a,h]anthracene rings a chemical characteristic of functional groups bound to a phenyl group.

3.2. Physicochemical parameters analysis.

Several physicochemical parameters have been used to design new drugs, such as molar volume (MV) and molar refraction (MR) [40-43]. Therefore, both MV and MR descriptors were determined using a previous method reported [44]. The results shown in Table 1 indicate that MV and MR were higher for 10 compared with 1 to 9. This phenomenon suggests that steric hindrance, conformational preferences, and internal rotation may be two factors that influence the biological activity exerted by 10 on some biological models.

Table 1. Physicochemical parameters involved in the chemical structure of Dibenzo derivatives (1 to 10).

Parameter	Compounds									
	1	2	3	4	5	6	7	8	9	10
MR (cm ³)	59.61	61.95	61.16	67.03	101.85	56.11	58.47	62.20	90.48	121.16
MV (cm ³)	168.10	165.50	152.90	188.50	228.10	138.80	142.70	145.50	230.00	281.90
IR	1.62	1.67	1.73	1.62	1.84	1.74	1.75	1.79	1.71	1.76
Density	1.15	1.19	1.38	1.21	1.28	1.32	1.28	1.37	1.28	1.24
Pol. (cm ³)	23.63	24.56	24.24	26.57	40.38	22.24	23.18	24.65	35.87	48.03
TPSA	9.23	0.00	50.44	17.07	26.02	33.37	39.16	20.23	32.59	29.10
cLogP	3.96	3.60	3.05	2.70	5.88	3.29	3.16	3.76	5.02	7.03
HBD	0	0	0	0	1	1	1	1	1	1
HBA	0	1	2	2	0	1	0	1	2	1

MR = Molar refraction
MV = Molar volume
IR = Index of refraction
Pol = Polarizability
TPSA = Polar surface area

3.3. Pharmacophore model.

Various theoretical methods have been developed for several years to design new drugs for treating different diseases.




Figure 3. The pharmacophore model was developed for Dibenzo derivatives using the LigandScout software. Hydrogen bond acceptors (HBA, red) and hydrogen bond donors (HBD, green).

For example, the pharmacophore model provides a new perspective on the design of new compounds useful for the development of new drugs; in this way, pharmacophore involves

several functional groups involved in the chemical structure of each compound which can be hydrogen bond donors (HBD), hydrogen bond acceptors (HBA), cations, anions, aromatic rings and hydrophobic area [45]. Based on these data, in this research, a pharmacophore model was developed using LigandScout software [17, 18] to evaluate the chemical characteristics of dibenzo derivatives (compounds 1 to 10).




Figure 4. The scheme shows the pharmacophore model for Dibenzo derivatives using the LigandScout software. Hydrogen bond acceptors (HBA, red) and hydrogen bond donors (HBD, green).

Figures 3 and 4 show a Pharmacophore model for compounds 1 to 10 (Dibenzo derivatives) using the LigandScout software. This pharmacophore involves different functional groups for each dibenzo derivative, which could interact with some biomolecules through hydrophobic or hydrogen bonds.

3.4. Interaction theoretical evaluation.

Some reports in the literature indicate that Dibenzo derivatives produce different effects in various biological systems [7-22]; however, there is little data on the interaction of dibenzo analogs with the enzyme aldosterone synthase. Here it is important to mention that some studies on the crystal structure of the complex of human aldosterone synthase with fadrozole show that fadrozole has a high affinity for aldosterone synthase (Kd 370 nM) with an inhibition constant of 354 nM. In addition, the imidazopyridine moiety of fadrozole makes contact in the active site cavity of the enzyme at amino acid residues 130, 487, I488, and 318 [46]. However, another study showed the interaction of an imidazole derivative with aldosterone synthase surface (PDB ID: 4dvq), which involved some amino acid residues such as Glu383, Phe381, Phe130, and Phe487 [47].

Table 2. Aminoacid residues involved in the interaction of Dibenzo derivatives (compounds 1-6) with 4fdh protein surface.

1	2	3	4	5
Trp116	Trp116	Trp116	Trp116	Phe130
Arg120	Phe130	Phe130	Phe130	Thr318
Phe130	Phe231	Phe231	Phe231	Phe381
Met230	Glu310	Phe381	Glu310	Phe487
Trp260	Thr318	Phe487	Ala313	Ile488
Glu310	Phe487		Thr318	
Ala313	Ile488			
Thr318				
Ile488				

Analyzing these data, in this study, a theoretical analysis on the interaction of ten Dibenzo derivatives with aldosterone synthase enzyme was evaluated using the 4fdh protein theoretical tool [48, 49] in a DockingServer software. The results showed differences in amino acid residues involved in the interaction of Dibenzo derivatives with 4fdh protein surface (PDB DOI: 10.2210/pdb4FDH/pdb) compared with fadrozole and isoquinoline derivatives (Table 2 and 3); this phenomenon could be due to differences in their chemical structure (Figure 1).

Table 3. Aminoacid residues involved in the coupling Dibenzo derivatives (compounds 7-10) with 4fdh protein surface.

6	7	8	9	10
Trp ₁₁₆	Arg ₁₁₀	Arg ₁₁₀	Trp ₁₁₆	Trp ₁₁₆
Phe ₁₃₀	Phe ₁₃₀	Met ₁₁₁	Arg ₁₂₀	Arg ₁₂₀
Trp ₂₆₀	Thr ₃₁₈	Phe ₁₃₀	Phe ₁₃₀	Phe ₁₃₀
Glu ₃₁₀	Phe ₃₈₁	Met ₂₃₈	Phe ₂₃₁	Phe ₂₃₁
Ala ₃₁₃	Glu ₃₈₃	Phe ₃₈₁	Trp ₂₆₀	Trp ₂₆₀
Thr ₃₁₈	Tyr ₄₈₅	Glu ₃₈₃	Glu ₃₁₀	Glu ₃₁₀
	Phe ₄₈₇	Phe ₄₈₇	Ala ₃₁₃	Ala ₃₁₃
	Ile ₄₈₈	Ile ₄₈₈	Phe ₄₈₇	Thr ₃₁₈
			Ile ₄₈₈	Phe ₃₈₁

3.5. Bond energies.

Some studies indicate that protein-ligand complex may depend on various types of energies, such as; free binding energy, electrostatic energy, total intermolecular energy, desolvation energy, and Van der Waals forces [50]. Therefore, in this study, different thermodynamic factors involved in the interaction of dibenzo derivatives with 4fdh protein surface were determined using DockingServer program.

Table 4. Thermodynamic parameters involved in the interaction of Dibenzo derivatives with the 4fdh-protein surface.

Compound	A	B	C	D	E	F
1	-8.11	1.14	-8.14	0.03	-8.11	565.69
2	-8.38	725.97	-8.36	-0.02	-8.38	567.98
3	-7.78	1.98	-8.01	-0.07	-8.08	567.74
4	-9.20	180.77	-9.24	0.04	-9.20	597.26
5	-10.34	26.33	-10.62	-0.02	-10.64	756.10
6	-6.51	16.93	-6.73	-0.08	-6.81	532.67
7	-7.25	4.85	-7.54	-0.01	-7.55	543.09
8	-7.28	4.60	-7.54	-0.04	-7.58	539.88
9	-9.69	78.61	-9.68	-0.31	-9.99	1095.28
10	-8.81	348.02	-9.80	-0.07	-9.88	1251.52

A = Est. Free Energy of Binding (kcal/mol)

B = Est. Inhibition Constant, Ki (mM)

C = vdW + Hbond + desolv Energy (kcal/mol)

D = Electrostatic Energy (kcal/mol)

E = Total Intermolec. Energy (kcal/mol)

F = Interact. Surface

11 = N-[4-(4-Cyano-phenyl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-propionamide [45].

12 = 4-[5-(5-Fluoro-pyrimidin-2-yloxy)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-methyl-benzonitrile [46].

The results (Table 4) display differences in energy requirements involved in the interaction of Dibenzo-derivatives with the 4fdh protein surface. Furthermore, other data showed that the inhibition constant (Ki) was lower for dibenzo derivatives 1, 3-9, compared to previously reported data for fadrozole (Ki = 354 nM) [46]. All these data indicate that compounds 1, 3-9 may have higher affinity by 4fdh protein surface, which may produce changes in the biological activity of aldosterone synthase enzyme translated as differences in the blood pressure.

4. Conclusions

This study's theoretical evaluation of the interaction of Dibenzo derivatives with aldosterone synthase is reported using DockingServer software. The results showed that Dibenzo derivatives 1, 3, 5-8, and 12 could act as aldosterone synthase inhibitors, translated as good compounds to decrease blood pressure. However, it is important to mention that some alternative experiments could be carried out in some biological models to evaluate other parameters, such as some allosteric site or some factor involved in the biological activity of the enzyme.

Funding

This research received no external funding.

Acknowledgments

None.

Conflicts of Interest

We declare that this manuscript has no conflict of financial interests (political, personal, religious, ideological, academic, intellectual, commercial, or otherwise) for publication.

References

1. Sakamaki, T.; Nakamuro, T.; Yamashita, K.; Hirata, K.; Shang, R.; Nakamura, E. B2N2-Doped Dibenzo [a, m] Rubicene: Modular Synthesis, Properties, and Coordination-Induced Color Tunability. *Chemistry of Materials* **2021**, *33*, 5337-5344, <https://doi.org/10.1021/acs.chemmater.1c01441>
2. Chakraborty, B.; Jana, U. Iron-catalyzed alkyne-carbonyl metathesis for the synthesis of 6, 7-dihydro-5H-dibenzo [c, e] azonines. *Organic & Biomolecular Chemistry*, **2021**, *19*, 10549-10553, <https://doi.org/10.1039/D1OB01258D>
3. Suzuki, Y.; Yamada, K.; Watanabe, K.; Kochi, T.; Ie, Y.; Aso, Y.; Kakiuchi, F. Synthesis of Dibenzo [h, rst] pentaphenes and Dibenzo [fg, qr] pentacenes by the Chemoselective C-O Arylation of Dimethoxyanthraquinones. *Organic Letters* **2017**, *19*, 3791-3794, <https://doi.org/10.1021/acs.orglett.7b01666>
4. Choi, Y.; Lim, H.; Lim, H.; Heo, J. One-pot transition-metal-free synthesis of dibenzo [b, f] oxepins from 2-halobenzaldehydes. *Organic Letters* **2012**, *14*, 5102-5105. <https://doi.org/10.1021/ol302371s>
5. Tokoro, Y.; Tanaka, K.; Chujo, Y. Synthesis of Dibenzo [b, f] silepins with a Benzoquinolyl Ligand. *Organic Letters* **2013**, *15*, 2366-2369, <https://doi.org/10.1021/ol400730n>
6. Laufer, S.; Ahrens, G.; Karcher, S.; Hering, J.; Niess, R. Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6, 11-Dihydro-dibenzo [b, e] oxepin-11-ones and Dibenzo [a, d] cycloheptan-5-ones: Novel p38 MAP Kinase Inhibitors. *Journal of Medicinal Chemistry* **2006**, *49*, 7912-7915, <https://doi.org/10.1021/jm061072p>
7. Yong, Y.; Li, J.; Gong, D.; Yu, T.; Wu, L.; Hu, C.; Ju, X. ERK1/2 mitogen-activated protein kinase mediates downregulation of intestinal tight junction proteins in heat stress-induced IBD model in pig. *Journal of Thermal Biology* **2021**, *101*, 103103, <https://doi.org/10.1016/j.jtherbio.2021.103103>
8. Yonezawa, T.; Kobayashi, Y.; Obara, Y. Short-chain fatty acids induce acute phosphorylation of the p38 mitogen-activated protein kinase/heat shock protein 27 pathway via GPR43 in the MCF-7 human breast cancer cell line. *Cellular Signalling* **2007**, *19*, 185-193. <https://doi.org/10.1016/j.cellsig.2006.06.004>
9. Huang, Z.; Chu, L.; Liang, J.; Tan, X.; Wang, Y.; Wen, J.; Zhang, B. H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p. *Hepatology* **2021**, *74*, 214-232, <https://doi.org/10.1002/hep.31673>

10. Pelaia, C.; Vatrella, A.; Gallelli, L.; Lombardo, N.; Sciacqua, A.; Savino, R.; Pelaia, G. Role of p38 mitogen-activated protein kinase in asthma and COPD: pathogenic aspects and potential targeted therapies. *Drug Design, Development and Therapy* **2021**, *15*, 1275, <https://doi.org/10.2147/DDDT.S300988>
11. Song, M.; Zhang, H.; Chen, Z.; Yang, J.; Li, J.; Shao, S.; Liu, J. Shikonin reduces hepatic fibrosis by inducing apoptosis and inhibiting autophagy via the platelet-activating factor-mitogen-activated protein kinase axis. *Experimental and Therapeutic Medicine* **2021**, *21*, 1-1, <https://doi.org/10.3892/etm.2020.9460>
12. Cano, C.; Saravanan, K.; Bailey, C.; Bardos, J.; Curtin, N.; Frigerio, M.; Griffin, R. J. 1-Substituted (Dibenzo [b, d] thiophen-4-yl)-2-morpholino-4 H-chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity. *Journal of Medicinal Chemistry* **2013**, *56*, 6386-6401, <https://doi.org/10.1021/jm400915j>
13. Vennila, K.; Selvakumar, B.; Satish, V.; Sunny, D.; Madhuri, S.; Elango, K. Structure-based design, synthesis, biological evaluation, and molecular docking of novel 10-methoxy dibenzo [b, h][1, 6] naphthyridinecarboxamides. *Medicinal Chemistry Research* **2021**, *30*, 133-141, <https://link.springer.com/article/10.1007/s00044-020-02645-x>.
14. Brahmhatt, G.; Sutariya, T.; Atara, H.; Parmar, N.; Gupta, V.; Lagunes, I.; Yadav, M. New pyrazolyl-dibenzo [b, e][1, 4] diazepinones: room temperature one-pot synthesis and biological evaluation. *Molecular Diversity* **2020**, *24*, 355-377, <https://doi.org/10.1007/s11030-019-09958-z>.
15. Gu, W.; Qiao, C.; Wang, S.; Hao, Y.; Miao, T. Synthesis and biological evaluation of novel N-substituted 1H-dibenzo [a, c] carbazole derivatives of dehydroabietic acid as potential antimicrobial agents. *Bioorganic & Medicinal Chemistry Letters* **2014**, *24*, 328-331, <https://doi.org/10.1016/j.bmcl.2013.11.009>
16. Edwards, A.; Marecki, J.; Byrd, A.; Gao, J.; Raney, K.. G-Quadruplex loops regulate PARP-1 enzymatic activation. *Nucleic Acids Research* **2021**, *49*, 416-431, <https://doi.org/10.1093/nar/gkaa1172>
17. Pandey, N.; Black, B. Rapid detection and signaling of DNA damage by PARP-1. *Trends in Biochemical Sciences* **2021**, *46*, 744-757, <https://doi.org/10.1016/j.tibs.2021.01.014>
18. Zhou, J.; Ji, M.; Wang, X.; Zhao, H.; Cao, R.; Jin, J.; Xu, B. Discovery of Quinazoline-2, 4 (1 H, 3 H)-dione Derivatives Containing 3-Substituted Piperizines as Potent PARP-1/2 Inhibitors— Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis. *Journal of Medicinal Chemistry* **2021**, *64*, 16711-16730, <https://doi.org/10.1021/acs.jmedchem.1c01522>
19. Li, S.; Li, X.; Zhang, T.; Zhu, J.; Liu, K.; Wang, D.; Meng, F. Novel 4, 5-dihydrospiro [benzo [c] azepine-1, 1'-cyclohexan]-3 (2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation. *Bioorganic Chemistry* **2021**, *111*, 104840, <https://doi.org/10.1016/j.bioorg.2021.104840>
20. Gómez-Jeria, J.; Ibertti-Arancibia, A. A DFT study of the relationships between electronic structure and dopamine D1 and D2 receptor affinity of a group of (S)-enantiomers of 11-(1, 6-dimethyl-1, 2, 3, 6-tetrahydropyridin-4-yl)-5H-dibenzo [b, e][1, 4] diazepines. *Chemistry Research Journal* **2021**, *6*, 116-131.
21. Lenzini, L.; Zanotti, G.; Bonchio, M.; Rossi, G. Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data. *Pharmacological Research* **2021**, *163*, 105332, <https://doi.org/10.1016/j.phrs.2020.105332>
22. Sydorhuk, L.; Dzhuryak, V.; Sydorhuk, A.; Levytska, S.; Petrynych, V.; Knut, R.; Sydorhuk, R. The cytochrome 11B2 aldosterone synthase gene rs1799998 single nucleotide polymorphism determines elevated aldosterone, higher blood pressure, and reduced glomerular filtration, especially in diabetic female patients. *Endocrine Regulations* **2020**, *54*, 217-226, <https://doi.org/10.2478/enr-2020-0024>
23. Rameshkumar, M.; Indu, P.; Arunagirinathan, N.; Venkatadri, B.; El-Serehy, H.; Ahmad, A. Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study. *Saudi Journal of Biological Sciences* **2021**, *28*, 448-458, <https://doi.org/10.1016/j.sjbs.2020.10.028>
24. Chen, J.; Zhang, H.; Chen, L.; Wu, B. New stress metabolite from *Bulbophyllum kwangtungense*. *Natural Product Communications* **2011**, *6*, 53-54, <https://pubmed.ncbi.nlm.nih.gov/21366045/>
25. Kargi, F. Biological oxidation of thianthrene, thioxanthene and dibenzothiophene by the thermophilic organism *Sulfolobus acidocaldarius*. *Biotechnology Letters* **1987**, *9*, 478-482, <https://link.springer.com/article/10.1007/BF01027456>.
26. Melkonyan, F.; Gevorgyan, V. Catalytic Transformations via C-H Activation. *Thieme*, **2015**, *XV*, 5-69, <https://doi.org/10.1055/sos-SD-217-00003>
27. Mihai, D.; Nitulescu, G.; Smith, J.; Hirsch, A.; Stecoza, C. Dengue virus replication inhibition by dibenzothiepin derivatives. *Medicinal Chemistry Research* **2019**, *28*, 320-328, <https://link.springer.com/article/10.1007/s00044-018-02286-1>.

28. Yamada, Y.; Tanaka, H.; Kubo, S.; Sato, S. Unveiling bonding states and roles of edges in nitrogen-doped graphene nanoribbon by X-ray photoelectron spectroscopy. *Carbon* **2021**, *185*, 342-367, <https://doi.org/10.1016/j.carbon.2021.08.085>
29. Jonas, U.; Hammer, E.; Schauer, F.; Bollag, J. Transformation of 2-hydroxydibenzofuran by laccases of the white rot fungi *Trametes versicolor* and *Pycnoporus cinnabarinus* and characterization of oligomerization products. *Biodegradation* **1997**, *8*, 321-327, <https://doi.org/10.1023/a:1008220120431>.
30. Khoshtariya, T.; Kakhbrishvili, M.; Kurkovskaya, L.; Suvorov, N. Indolobenzofurans. 1. Synthesis of isomeric indolobenzofurans. *Chemistry of Heterocyclic Compounds* **1984**, *20*, 1123-1127.
31. Aranda, E.; Kinne, M.; Kluge, M.; Ullrich, R.; Hofrichter, M. Conversion of dibenzothiophene by the mushrooms *Agrocybe aegerita* and *Coprinellus radians* and their extracellular peroxygenases. *Applied Microbiology and Biotechnology* **2009**, *82*, 1057-1066, <https://doi.org/10.1007/s00253-008-1778-6>.
32. Higgins, S.; Morris, D.; Muir, K.; Ryder, K. The chiral oxime of 13 H-dibenzo (a, i) fluoren-13-one. *Canadian Journal of Chemistry* **2004**, *82*, 1625-1628, <https://doi.org/10.1139/v04-133>.
33. N-dibenzo[a,h]anthracen-7-ylbutanamide. <https://pubchem.ncbi.nlm.nih.gov/compound/90486931>
34. Türker, L. Interaction of Carmustine Tautomers with Adenine-DFT Study. *Earthline Journal of Chemical Sciences* **2021**, *5*, 63-76, <https://doi.org/10.34198/ejcs.5121.6376>,
35. Hariyanti, H.; Kurmardi, K.; Yanuar, A.; Hayun, H. Ligand based pharmacophore modeling, virtual screening, and molecular docking studies of asymmetrical hexahydro-2H-indazole analogs of curcumin (AIACs) to discover novel estrogen receptors alpha (ER α) inhibitor. *Indonesian Journal of Chemistry* **2021**, *21*, 137-147, <https://doi.org/10.22146/ijc.54745>
36. Yoshimori, A.; Asawa, Y.; Kawasaki, E.; Tasaka, T.; Matsuda, S.; Sekikawa, T.; Kanai, C. Design and synthesis of DDR1 inhibitors with a desired pharmacophore using deep generative models. *ChemMedChem* **2021**, *16*, 955-958, <https://doi.org/10.1002/cmdc.202000786>
37. Luo, G.; Lu, F.; Qiao, L.; Chen, X.; Li, G.; Zhang, Y. Discovery of potential inhibitors of aldosterone synthase from Chinese herbs using pharmacophore modeling, molecular docking, and molecular dynamics simulation studies. *BioMed Research International* **2016**, 1-8, <http://dx.doi.org/10.1155/2016/4182595>
38. Ankley, G.; Kahl, M.; Jensen, K.; Hornung, M.; Korte, J.; Makynen, E.; Leino, R. Evaluation of the aromatase inhibitor fadrozole in a short-term reproduction assay with the fathead minnow (*Pimephales promelas*). *Toxicological Sciences* **2002**, *67*, 121-130, <https://doi.org/10.1093/toxsci/67.1.121>.
39. Choudhary, V.; Bhatt, A.; Dash, D.; Sharma, N. DFT calculations on molecular structures, HOMO-LUMO study, reactivity descriptors and spectral analyses of newly synthesized diorganotin (IV) 2-chloridophenylacetohydroxamate complexes. *Journal of Computational Chemistry* **2019**, *40*, 2354-2363, <https://doi.org/10.1002/jcc.26012>
40. Tiwari, V.; Pande, R. Molecular descriptors of N-Arylhydroxamic acids: a tool in drug design. *Chemical Biology & Drug Design* **2006**, *68*, 225-228, <https://doi.org/10.1111/j.1747-0285.2006.00433.x>
41. Mondal, M.; Basak, S.; Choudhury, S.; Ghosh, N.; Roy, M. Investigation of molecular interactions insight into some biologically active amino acids and aqueous solutions of an anti-malarial drug by physicochemical and theoretical approach. *Journal of Molecular Liquids* **2021**, *341*, 116933, <https://doi.org/10.1016/j.molliq.2021.116933>
42. Schnackenberg, L.; Beger, R. Whole-molecule calculation of log P based on molar volume, hydrogen bonds, and simulated ¹³C NMR spectra. *Journal of Chemical Information and Modeling* **2005**, *45*, 360-365, <https://doi.org/10.1021/ci049643e>
43. Clark, D. What has polar surface area ever done for drug discovery?. *Future Medicinal Chemistry* **2011**, *3*, 469-484, <https://doi.org/10.4155/fmc.11.1>
44. Hammoudan, I.; Matchi, S.; Bakhouch, M.; Belaidi, S.; Chtita, S. QSAR Modelling of Peptidomimetic Derivatives towards HKU4-CoV 3CLpro Inhibitors against MERS-CoV. *Chemistry* **2021**, *3*, 391-401, <https://doi.org/10.3390/chemistry3010029>
45. Kim, K.; Kim, N.; Seong, B. Pharmacophore-based virtual screening: a review of recent applications. *Expert Opinion on Drug Discovery* **2010**, *5*, 205-222, <https://doi.org/10.1517/17460441003592072>.
46. Strushkevich, N.; Gilep, A.; Shen, L.; Arrowsmith, C.; Edwards, A.; Usanov, S.; Park, H. Structural insights into aldosterone synthase substrate specificity and targeted inhibition. *Molecular Endocrinology* **2013**, *27*, 315-324, <https://doi.org/10.1210/me.2012-1287>.
47. Yin, L.; Hu, Q.; Emmerich, J.; Lo, M.; Metzger, E.; Ali, A.; Hartmann, R. Novel pyridyl- or isoquinoliny- substituted indolines and indoles as potent and selective aldosterone synthase inhibitors. *Journal of medicinal Chemistry* **2014**, *57*, 5179-5189, <https://doi.org/10.1021/jm500140c>

48. Browne, L.; Gude, C.; Rodriguez, H.; Steele, R. E.; Bhatnager, A. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. *Journal of Medicinal Chemistry* **1991**, *34*, 725-736, <https://doi.org/10.1021/jm00106a038>
49. Demers, L. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. *Breast Cancer Research and Treatment* **1994**, *30*, 95-102, <https://doi.org/10.1007/bf00682744>.
50. Figueroa-Valverde, L.; Francisco, D.; Marcela, R.; Virginia, M.; Elizabeth, M.; Maria, L.; Jhair, C. Design and Synthesis of a Diaza-bicyclo-naphthalen-oxiranyl-methanone Derivative. Theoretical Analysis of Their Interaction with Cytochrome P450-17A1. *Chemical Methodologies* **2019**, *3*, 194-210, <https://doi.org/10.22034/chemm.2018.147492.1083>.